Mesoblast Limited (MESO) rose 12.40 percent to $12.24 on Tuesday after announcing it reached alignment with the FDA on requirements to file a Biologics License Application for Revascor, aimed at treating ischemic heart failure patients with reduced ejection fraction and inflammation.
Shares opened at $12.00, moved between $11.72 and $12.50 on the Nasdaq, and traded 254,644 shares, above the 206,195 averages, as investors welcomed the FDA progress.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.